Form 4: Arcellx Chief Medical Officer Christopher Heery Reports Stock Sales to Cover Tax Obligations

Christopher Heery, Chief Medical Officer of Arcellx, Inc., reports selling shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

Summary

• On February 24, 2025, Christopher Heery, the Chief Medical Officer of Arcellx, Inc., reported the sale of Arcellx common stock.
• These sales were executed to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs).
• The sales were broker-assisted.
• Heery sold 4,370 shares at a weighted average price of $63.1391, 5,577 shares at a weighted average price of $64.2568, and 208 shares at a weighted average price of $64.8778.
• Following these transactions, Heery directly owns 37,486 shares of Arcellx common stock.
• Heery also exercised 22,556 restricted stock units on February 7, 2025.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing related to stock sales for tax purposes, indicating a neutral sentiment.

Industry Context

Form 4 filings are a routine part of insider trading regulations, providing transparency into the transactions of company executives and directors. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Stakeholder Impact

• The stock sales could have a minor impact on shareholders due to the increased supply of shares in the market, but the impact is likely to be minimal given the relatively small number of shares sold.

Key Dates

Keywords

Arcellx, ACLX, Christopher Heery, Chief Medical Officer, Form 4, Stock Sale, Restricted Stock Units, Tax Withholding, Beneficial Ownership, Securities